Ampligen^® as a Potential Treatment of SARS-CoV-2

• • Potentially broad-spectrum immune system response against SARS-CoV-2 (COVID-19)

  • Uniquely targets TLR3 without activation of the inflammatory cytosolic helicases

  • Potential efficacy may not be impacted by viral mutations, such as Delta, Omicron or future given mechanism of action

  • Demonstrated complete protection (100% survival) against SARS-CoV-1, Ebola virus disease, and Western Equine Encephalitis virus in preclinical (animal) studies

Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, Smee DF, Barnard DL. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology. 2009 Dec 20;395(2):210-22. doi: 10.1016/j.virol.2009.09.023. Epub 2009 Oct 22. PMID: 19853271; PMCID: PMC2787736.